Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Primary Central Nervous System Lymphoma: Evolving Biologic Insights and Recent Therapeutic Advances.

Clinical lymphoma, myeloma & leukemia - 1 Feb 2021

Chihara Dai, Dunleavy Kieron

Abstract excerpt

Primary central nervous system lymphoma (PCNSL) is a rare and clinically aggressive disease entity associated with poor survival. Though high-dose methotrexate-based immunochemotherapy approaches are effective at inducing responses, few patients experience long-term durable remissions. Recently, novel insights into the biology of this unique disease have been elucidated and have paved the way for the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Agammaglobulinaemia Tyrosine Kinase
Share to Central Nervous System Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Combined Modality Therapy

Share to Immune Checkpoint Inhibitors

Share to Immunotherapy, Adoptive

Share to Lymphoma, Non-Hodgkin

Share to Progression-Free Survival

Share to Receptors, Chimeric Antigen

Source

Identifiers

PMID: 33288483
DOI: 10.1016/j.clml.2020.10.015

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Primary Central Nervous System Lymphoma: Evolving Biologic Insights and Recent Therapeutic Advances.PMID 33288483Read ↗

Insights into the biology of primary central nervous system lymphoma.Semantic proximity Read ↗

Primary Central Nervous System Lymphoma: Molecular Pathogenesis and Advances in TreatmentSemantic proximity Read ↗

Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma.Semantic proximity Read ↗

Primary CNS lymphoma commonly expresses immune response biomarkersSemantic proximity Read ↗

Emerging insights into origin and pathobiology of primary central nervous system lymphoma.Semantic proximity Read ↗

Pathology and new insights in central nervous system lymphomas.Semantic proximity Read ↗

Malignant lymphoma: pathophysiology and current therapy.Semantic proximity Read ↗

Molecular and clinical diversity in primary central nervous system lymphoma.Semantic proximity Read ↗

A Phase II Study Assessing Long-term Response to Ibrutinib Monotherapy in Recurrent or Refractory CNS Lymphoma.Semantic proximity Read ↗

CD19-directed CAR T-cell therapy for treatment of primary CNS lymphomaSemantic proximity Read ↗

Mutational analysis of primary central nervous system lymphoma.Semantic proximity Read ↗

A retrospective analysis of clinicopathological and genetic features of synchronous CNS and systemic DLBCL at diagnosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.